Zobrazeno 1 - 10
of 2 524
pro vyhledávání: '"gonadotropin releasing hormone agonist"'
Publikováno v:
BMC Women's Health, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Conservative surgery for adenomyosis has been shown to be effective. However, risk factors for postoperative recurrence have yet to be clarified. In this study, we aimed to determine the recurrence rate after conservative surgery
Externí odkaz:
https://doaj.org/article/3668cc9620054146be70ca2f577ab7bb
Autor:
Gaby Moawad, Youssef Youssef, Arrigo Fruscalzo, Slim Khedhri, Hani Faysal, Paul Pirtea, Benedetta Guani, Alexandre Vallée, Jean Marc Ayoubi, Anis Feki
Publikováno v:
Frontiers in Reproductive Health, Vol 6 (2024)
Adenomyosis is a commonly encountered pathology in women of reproductive age and frequently coexists with infertility. The effect of adenomyosis on fertility, particularly on in vitro fertilisation and intracytoplasmic sperm injection outcomes, is no
Externí odkaz:
https://doaj.org/article/9751ed7c94d94e828e2e29a84d0b4c81
Publikováno v:
PeerJ, Vol 12, p e18635 (2024)
Background The basal luteinizing hormone (LH) and the prior LH to follicle-stimulating hormone (FSH) ratio (LH/FSH) in polycystic ovarian syndrome (PCOS) are generally higher than those in non-PCOS patients and the general population. The potential n
Externí odkaz:
https://doaj.org/article/86f6a2369b274631964bf84c677e07ea
Autor:
Seyedeh houra Hashemi, Maryam Hafezi, Arezoo Arabipoor, Maryam Zareei, Samira Vesali, Poopak Eftekhari-Yazdi
Publikováno v:
International Journal of Fertility and Sterility, Vol 18, Iss Suppl 1, Pp 48-54 (2024)
Background: There is an ongoing debate about the optimal dosage of gonadotropin-releasing hormone (GnRH)agonist for oocyte triggering in polycystic ovarian syndrome (PCOS) patients at risk for ovarian hyperstimulation syndrome(OHSS). In this study, w
Externí odkaz:
https://doaj.org/article/499907102d694d00bdaf3b335f4fdb71
Publikováno v:
Journal of Clinical & Translational Endocrinology, Vol 37, Iss , Pp 100368- (2024)
The subject of polycystic ovary syndrome (PCOS) has been extensively covered in the literature; however, there is a paucity of data regarding eumenorrheic women with hyperandrogenism and/or hyperandrogenemia without ultrasound evidence of PCO morphol
Externí odkaz:
https://doaj.org/article/dcbc4c7ee8164d77a5f4546340e1004f
Autor:
Jieyu Wang, Xiaomei Tong, Haiyan Zhu, Minling Wei, Xiaona Lin, Xiufen Wang, Huaying Yu, Fang Hong, Songying Zhang
Publikováno v:
Taiwanese Journal of Obstetrics & Gynecology, Vol 63, Iss 1, Pp 57-63 (2024)
Objective: To compare the reproductive pregnancy outcomes of pretreatment with long-acting gonadotropin-releasing hormone agonist (GnRH-a) plus hormone replacement therapy (HRT) with HRT-only cycles, and investigate differences between single polypec
Externí odkaz:
https://doaj.org/article/293af72d37414166a22c2104cd206415
Autor:
Natalie J. Nokoff, Samantha Bothwell, John D. Rice, Melanie G. Cree, Megan M. Kelsey, Kerrie L. Moreau, Philip Zeitler, Kristen J. Nadeau
Publikováno v:
Journal of Clinical & Translational Endocrinology, Vol 36, Iss , Pp 100356- (2024)
Background: 1.8% of youth identify as transgender; a growing proportion are transgender male (female sex, male gender identity). Many receive gonadotropin releasing hormone agonist (GnRHa) therapy to suppress endogenous puberty and/or will start test
Externí odkaz:
https://doaj.org/article/75027ed3284a4ebdb8f7bcec3b80040c
Publikováno v:
PeerJ, Vol 12, p e17447 (2024)
Objective To investigate the effect of GnRH agonist (GnRH-a) down-regulation prior to hormone replacement treatment (HRT) to prepare the endometrium in frozen embryo transfer (FET) cycles in women of different ages. Methods This was a retrospective s
Externí odkaz:
https://doaj.org/article/f9acb8b4e79849c7911b9321c949ef59
Autor:
Safa Najafi, Maryam Ansari, Zahra Omidi, Asiie Olfatbakhsh, Shiva Moghadam, Esmat-o-Sadat Hashemi, Niki Najafi, Shahpar Haghighat
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Diphereline is a Gonadotropin-Releasing Hormone agonist commonly used in patients with breast cancer. This study aimed to compare the efficacy and safety of one-month and three-month Microrelin injections produced by Homa Pharmed
Externí odkaz:
https://doaj.org/article/aa9d7ad4ad184ec2a5dc04052336c5a5
Publikováno v:
International Journal of General Medicine, Vol Volume 16, Pp 4357-4364 (2023)
Ting Deng, Yin Lin, Li Chen, Jun-Ying Jiang Department of Obstetrics and Gynecology, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, 350001, Peopl
Externí odkaz:
https://doaj.org/article/1e6fff5b10884aa282967736b562054e